    [Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
    [Notices]
    [Page 53401]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 2020-18979]

    -----------------------------------------------------------------------

    DEPARTMENT OF JUSTICE

    Antitrust Division

    Notice Pursuant to the National Cooperative Research and
    Production Act of 1993--Medical CBRN Defense Consortium

        Notice is hereby given that, on July 30, 2020, pursuant to Section
    6(a) of the National Cooperative Research and Production Act of 1993,
    15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium
    (``MCDC'') has filed written notifications simultaneously with the
    Attorney General and the Federal Trade Commission disclosing changes in
    its membership. The notifications were filed for the purpose of
    extending the Act's provisions limiting the recovery of antitrust
    plaintiffs to actual damages under specified circumstances.
    Specifically, Abiogenix, Inc.; Rochester, MI; ANP Technologies, Inc.;
    Newark, DE; Arcturus UAV, Inc.; Petaluma, CA; AstraZeneca
    Pharmaceuticals, LP; Gaithersburg, MD; Blade Therapeutics, Inc.; South
    San Francisco, CA; Celularity, Inc.; New York, NY; Commonwealth Trading
    Partners, Inc.; Alexandria, VA; Cytonus Therapeutics, Inc.; Columbus,
    OH; D. Wheatley Enterprises, Inc.; Belcamp, MD; ElectroNucleics, Inc.;
    Placentia, CA; Fast-Track Drugs & Biologics, LLC; Poolesville, MD; Fry
    Laboratories, LLC; Scottsdale, AZ; Full Effect Biotech, Inc.; Kansas
    City, KS; GAP Solutions, Inc.; Herndon, VA; iBio CDMO LLC; Bryan, TX;
    iBio, Inc.; New York, NY; Massachusetts Eye and Ear Infirmary; Boston,
    MA; MicroHealth LLC; Vienna, VA; Novavax, Inc.; Gaithersburg, MD;
    Pfizer, Inc.; New York, NY; Planet Biotechnology, Inc.; Hayward, CA;
    Primmune Therapeutics, Inc.; San Diego, CA; Quantum Leap Healthcare
    Collaborative; San Francisco, CA; QuickSilver Analytics, Inc.;
    Hampstead, NC; Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; Resonant
    Sensors, Inc.; Arlington, TX; Rubix Strategies LLC; Lawrence, MA; Shift
    Labs, Inc.; Seattle, WA; SiO2 Medical Products, Inc.; Auburn, AL; Space
    Information Laboratories; Santa Maria, CA; Teledyne Brown Engineering,
    Inc.; Huntsville, AL; TensorX Inc.; Vienna, VA; Tunnell Consulting,
    Inc.; Bethesda, MD; Ultimaxx Health, Inc.; Boca Raton, FL; University
    of Delaware on behalf of NIIMBL; Newark, DE; University of Louisville;
    Louisville, KY; Vaxart, Inc.; South San Francisco, CA; Zeteo Biomedical
    LLC; Austin, TX have been added as parties to this venture.
        Also, Onyx Government Services; Centreville, VA; Space Information
    Laboratories; Santa Maria, CA, Valaria Technical Consultants, LLC;
    Westminister, MD have withdrawn from this venture.
        No other changes have been made in either the membership or planned
    activity of the group research project. Membership in this group
    research project remains open, and MCDC intends to file additional
    written notifications disclosing all changes in membership.
        On November 13, 2015, MCDC filed its original notification pursuant
    to Section 6(a) of the Act. The Department of Justice published a
    notice in the Federal Register pursuant to Section 6(b) of the Act on
    January 6, 2016 (81 FR 513).
        The last notification was filed with the Department on April 30,
    2020. A notice was published in the Federal Register pursuant to
    Section 6(b) of the Act on May 19, 2020 (85 FR 29976).

    Suzanne Morris,
    Chief, Premerger and Division Statistics, Antitrust Division.
    [FR Doc. 2020-18979 Filed 8-27-20; 8:45 am]
    BILLING CODE P